Injectafer denied for failing step therapy by Humana?

Humana's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Injectafer Under Step Therapy

A step-therapy denial means Humana requires documentation that one or more lower-cost or preferred iron replacement agents were tried before Injectafer (ferric carboxymaltose) will be authorized. Step therapy is among the most common denial types for IV iron products, and it is also one of the most frequently reversed on appeal — because many patients have a documented history with oral or other parenteral iron agents that qualifies them for the next step.

The key to overturning this denial is demonstrating that the required step(s) have been satisfied — either through actual prior treatment with the preferred agent, or through a documented clinical reason why the step-therapy requirement should be waived.

## Federal Appeal Framework

ACA §2719 provides the right to external review by an accredited IRO after exhausting Humana's internal process. ERISA §503 applies to employer plans and guarantees full-and-fair review. The external-review filing window is typically four months from the final internal denial. Expedited review is available when delay would seriously jeopardize health, with a 72-hour turnaround requirement.

Note: many states have enacted step-therapy reform laws that limit how insurers may apply step-therapy requirements — check your state's insurance commissioner resources if you are on a fully-insured plan.

## Concrete Appeal Steps

1. Obtain from Humana the specific step-therapy protocol in writing — which agents are required, in what order, and for how long. 2. Review your patient's treatment history for any prior oral or IV iron therapy that satisfies a step. 3. If a required step was completed: document it with dates, prescribing provider, doses given, and clinical outcome. 4. If a required step was not completed: have your prescriber document the clinical reason for bypassing it (intolerance, malabsorption preventing oral absorption, clinical urgency, etc.). 5. Submit the internal appeal with the step-history documentation within Humana's stated deadline. 6. If denied, proceed to external review.

## Documentation to Gather

• Diagnosis confirmation: Chart notes and labs confirming the diagnosis and severity of iron deficiency.
• Step-therapy history: A chronological list of each required prior agent tried, with start/stop dates, doses administered, and documented clinical outcomes — including why each step was insufficient.
• Waiver justification (if applicable): Clinical notes explaining why a required step cannot safely or effectively be completed for this patient, referencing the applicable clinical guideline organization.
• Prescriber medical-necessity letter: Addresses each step in Humana's protocol and maps the patient's history or clinical exception to each requirement, referencing the FDA-approved Injectafer label.

## Criteria-Mapping Structure

Obtain Humana's step-therapy criteria for IV iron replacement and the FDA-approved Injectafer prescribing label. Build a table:

| Step-therapy requirement | Satisfaction evidence or waiver basis | |---|---| | Required Step 1 agent tried | [Agent name, dates, doses, outcome] | | Required Step 2 agent tried (if applicable) | [Agent name, dates, doses, outcome] | | Clinical exception basis (if applicable) | [Prescriber letter rationale, chart reference] | | Injectafer indication confirmed | [FDA label section, prescriber statement] |

Step-therapy appeals supported by a complete chronological treatment history with documented outcomes are among the strongest appeals at both internal and external review.